Monoclonal Antibodies in Lymphoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 169

Special Issue Editor

E-Mail Website
Guest Editor
U.O.C. di Ematologia, Azienda Ospedaliera Papardo, 98158 Messina, Italy
Interests: hematological diagnosis and treatment; lymphoma; clinical trials

Special Issue Information

Dear Colleagues,

The introduction of monoclonal antibodies (MoAbs) into clinical practice has significantly improved the prognosis of many hematological malignancies, representing  a milestone in the field of precision medicine.

Used in monotherapy or, more often, in combination with chemotherapy, MoAbs are currently essential in the treatment of lymphoid neoplasms.

MoAbs are able to target specific cancer antigens, using direct or indirect immunological killing to address cytotoxic agents to neoplastic cells, to recruit and activate immune effector cells, and to antagonize cell exhaustion.      

In this Special Issue, we would like to provide an overview of the biological basis and the current clinical use of MoAbs and of the optimal combination regimens and sequential schemes, with a look towards future therapeutic perspectives.

Dr. Donato Mannina
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • monoclonal antibodies
  • immunotherapy
  • drug immunoconiugates
  • bispecific antibodies
  • checkpoints inhibitors
  • NHL
  • HL
  • CLL

Published Papers

This special issue is now open for submission.
Back to TopTop